Research Advances on the Pathogenesis and Treatment of Hemolytic Uremic Syndrome --Review.
10.19746/j.cnki.issn.1009-2137.2022.02.053
- Author:
Wan-Ying LIU
1
;
Yi XIAO
2
Author Information
1. Department of Hematology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.
2. Department of Hematology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China,E-mail: yixiao@tjh.tjmu.edu.cn.
- Publication Type:Review
- Keywords:
Eculizumab;
Lavalizumab;
Ravulizumab;
Shiga toxin;
hemolytic uremic syndrome
- MeSH:
Complement System Proteins/therapeutic use*;
Hemolytic-Uremic Syndrome/therapy*;
Humans;
Mutation
- From:
Journal of Experimental Hematology
2022;30(2):636-640
- CountryChina
- Language:Chinese
-
Abstract:
Hemolytic uremic syndrome (HUS) is clinically rare, with high mortality and case fatality rates. In recent years, the research on HUS has been intensified and the pathophysiological mechanism has been continuously improved. At present, the main mechanism of pathogenesis is the excessive activation of complement alternative pathways mediated by complement-related gene mutations or the existence of antibodies. The treatment methods and strategies are also constantly updated, mainly including complement-blocking drugs such as Eculizumab, Lavalizumab, and Ravulizumab. In this review, the new developments in the pathogenesis and treatment of HUS is summarized, and provide references for the clinical treatment of HUS.
